Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway

exactis

Exactis is pleased to be working with Dr. Sébastien Perreault from CHU Ste-Justine on the TRAM-01 study, “ Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway”.

This study is led by Dr. Sébastien Perreault and the main objective is to determine the objective response rate of daily trametinib as a single agent for treatment of progressing/refractory tumors with MAPK/ERK pathway activation.

The trial started in August 2018 and will enroll up to 150 patients across 7 canadian sites. Accrual is on target and the last patient should be enrolled in Q1 2022 and completion of follow-up is expected in Q3 2026.

https://clinicaltrials.gov/ct2/show/NCT03363217?term=tram-01&draw=2&rank=1